| pubmed-article:15681764 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15681764 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15681764 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:15681764 | lifeskim:mentions | umls-concept:C0021641 | lld:lifeskim |
| pubmed-article:15681764 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:15681764 | lifeskim:mentions | umls-concept:C0011847 | lld:lifeskim |
| pubmed-article:15681764 | lifeskim:mentions | umls-concept:C0449258 | lld:lifeskim |
| pubmed-article:15681764 | pubmed:dateCreated | 2005-1-31 | lld:pubmed |
| pubmed-article:15681764 | pubmed:abstractText | Repeated ingestion of insulin has been suggested as an immune tolerization therapy to prevent immune-mediated (type 1) diabetes. We performed a placebo-controlled, two-dose, oral insulin tolerance trial in newly diagnosed (< 2 years) diabetic patients who had required insulin replacement for less than 4 weeks and were found to have cytoplasmic islet cell autoantibodies (ICAs). No oral hypoglycemic agents were permitted during the trial. Endogenous insulin reserves were estimated at six-month intervals by plasma C-peptide responses to a mixed meal. Positive ICAs were found in 262 (31%) of the 846 patients screened. Of the 197 who agreed to participate, 187 could be followed for 6 to 36 months. Endogenous insulin retention was dependent upon initial stimulated C-peptide response, age at diabetes onset, and numbers of specific islet cell autoantibodies found. Oral insulin improved plasma C-peptide responses in patients diagnosed at ages greater than 20 years, best seen at the low (1 mg/day) over the high (10 mg/day) insulin dose (P = .003 and P = .01, respectively). In patients diagnosed before age 20 years, the 1 mg dose was ineffective, whereas the 10 mg dose actually accelerated C-peptide loss (P = .003). There were no adverse effects. If confirmed, these findings suggest that diabetic patients over age 20 years with ICA evidence of late-onset immune-mediated diabetes should be considered for oral insulin at 1 mg/day to better retain endogenous insulin secretion. | lld:pubmed |
| pubmed-article:15681764 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15681764 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15681764 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15681764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15681764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15681764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15681764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15681764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15681764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15681764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15681764 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15681764 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:15681764 | pubmed:issn | 0077-8923 | lld:pubmed |
| pubmed-article:15681764 | pubmed:author | pubmed-author:RaskinPhilipP | lld:pubmed |
| pubmed-article:15681764 | pubmed:author | pubmed-author:MarkerJohnJ | lld:pubmed |
| pubmed-article:15681764 | pubmed:author | pubmed-author:MaclarenNoel... | lld:pubmed |
| pubmed-article:15681764 | pubmed:author | pubmed-author:BodeBruceB | lld:pubmed |
| pubmed-article:15681764 | pubmed:author | pubmed-author:RapaportRober... | lld:pubmed |
| pubmed-article:15681764 | pubmed:author | pubmed-author:SchatzDesmond... | lld:pubmed |
| pubmed-article:15681764 | pubmed:author | pubmed-author:KrischerJeffr... | lld:pubmed |
| pubmed-article:15681764 | pubmed:author | pubmed-author:VargasAlfonso... | lld:pubmed |
| pubmed-article:15681764 | pubmed:author | pubmed-author:SchwartzSherw... | lld:pubmed |
| pubmed-article:15681764 | pubmed:author | pubmed-author:MaloneJohnJ | lld:pubmed |
| pubmed-article:15681764 | pubmed:author | pubmed-author:RogersDouglas... | lld:pubmed |
| pubmed-article:15681764 | pubmed:author | pubmed-author:ZeidlerAdinaA | lld:pubmed |
| pubmed-article:15681764 | pubmed:author | pubmed-author:Ergun-Longmir... | lld:pubmed |
| pubmed-article:15681764 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15681764 | pubmed:volume | 1029 | lld:pubmed |
| pubmed-article:15681764 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15681764 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15681764 | pubmed:pagination | 260-77 | lld:pubmed |
| pubmed-article:15681764 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:15681764 | pubmed:meshHeading | pubmed-meshheading:15681764... | lld:pubmed |
| pubmed-article:15681764 | pubmed:meshHeading | pubmed-meshheading:15681764... | lld:pubmed |
| pubmed-article:15681764 | pubmed:meshHeading | pubmed-meshheading:15681764... | lld:pubmed |
| pubmed-article:15681764 | pubmed:meshHeading | pubmed-meshheading:15681764... | lld:pubmed |
| pubmed-article:15681764 | pubmed:meshHeading | pubmed-meshheading:15681764... | lld:pubmed |
| pubmed-article:15681764 | pubmed:meshHeading | pubmed-meshheading:15681764... | lld:pubmed |
| pubmed-article:15681764 | pubmed:meshHeading | pubmed-meshheading:15681764... | lld:pubmed |
| pubmed-article:15681764 | pubmed:meshHeading | pubmed-meshheading:15681764... | lld:pubmed |
| pubmed-article:15681764 | pubmed:meshHeading | pubmed-meshheading:15681764... | lld:pubmed |
| pubmed-article:15681764 | pubmed:meshHeading | pubmed-meshheading:15681764... | lld:pubmed |
| pubmed-article:15681764 | pubmed:meshHeading | pubmed-meshheading:15681764... | lld:pubmed |
| pubmed-article:15681764 | pubmed:meshHeading | pubmed-meshheading:15681764... | lld:pubmed |
| pubmed-article:15681764 | pubmed:meshHeading | pubmed-meshheading:15681764... | lld:pubmed |
| pubmed-article:15681764 | pubmed:meshHeading | pubmed-meshheading:15681764... | lld:pubmed |
| pubmed-article:15681764 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15681764 | pubmed:articleTitle | Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. | lld:pubmed |
| pubmed-article:15681764 | pubmed:affiliation | Division of Pediatric Endocrinology, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, USA. | lld:pubmed |
| pubmed-article:15681764 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15681764 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15681764 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:15681764 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:15681764 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15681764 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15681764 | lld:pubmed |
